Clarus Corporation has been upgraded from a Sell to a speculative Hold due to a significant improvement in its profit outlook. The company now expects EBITDA between $12 million and $13 million and operating cash flow of $12.5 million, helped by cost cuts, a favorable product mix, and a $6.1 million tariff refund. Despite these positive changes and a debt-free balance sheet, concerns about macroeconomic risks and stagnant revenue limit optimism for the stock's future performance.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Ethereum's price fell below the critical $2,700 level on Binance spot trading, reaching $2,696 as of 9:37 a.m. ET on September 28. This break is notable because $2,700 is a closely watched support level by traders. Despite this drop, ETH's price was ...
World Assets, Ltd. has completed multiple over-the-counter (OTC) sales totaling $49 million in the past month, involving their token WLD. Each transaction is subject to a one-year lockup period, meaning the tokens cannot be sold or transferred during...
